Source: Virtual Congress 2021 – Novel imaging analysis methodologies in diffuse lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Strange (Charleston, United States of America), N. Mcelvaney (Dublin, Ireland), C. Vogelmeier (Marburg, Germany), M. Marin-Galiano (Düsseldorf, Germany), M. Haensel (Marburg, Germany), X. Zhang (King of Prussia, United States of America), Y. Chen (King of Prussia, United States of America), O. Vit (Bern, Switzerland), M. Wencker (Loerzweiler, Germany), K. Chapman (Toronto, Canada). The effect of exacerbations on lung density in relation to patient characteristics in the RAPID-RCT trial of alpha-1 antitrypsin therapy. 349

Member's Comments

No comment yet.

Related content which might interest you: Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 The prognostic value of CT-based lung density histograms in patients with severe alpha-1 antitrypsin deficiency Source: Eur Respir J 2004; 24: Suppl. 48, 296s Year: 2004 Effect of exacerbations on lung density in alpha-1 antitrypsin deficiency: Subgroup analysis of the RAPID trial programme Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 The withdrawal of replacement therapy and outcomes in alpha-1 antitrypsin deficiency lung transplant recipients Source: Eur Respir J, 53 (5) 1900055; 10.1183/13993003.00055-2019 Year: 2019 Homecare setting of longterm augmentation therapy in alpha1 antitrypsin defiency patients leads to clinical stabilization Source: International Congress 2017 – New frontiers in home care management of chronic lung diseases Year: 2017 Characteristics of COPD patients and alpha-1 antitrypsin deficiency at outpatient respiratory clinics. The EPOCONSUL study. Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Comparison of exercise training responses in COPD patients with and without Alpha-1 antitrypsin deficiency Source: International Congress 2018 – Latest advances in pulmonary rehabilitation assessment and content Year: 2018 Differences in training response between patients with alpha-1 antitrypsin deficiency and COPD patients Source: International Congress 2015 – Best abstracts in functional capacity in chronic lung diseases Year: 2015 Patterns of exacerbations in alpha 1 antitrypsin deficiency (AATD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 The effect preoperative intervention with long-acting bronchodilator for untreated patients with obstructive lung disease Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation Source: Eur Respir J, 50 (3) 1700962; 10.1183/13993003.00962-2017 Year: 2017 The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 433s Year: 2002 Does atorvastatin have effect on lung function and morbidity as add-on therapy in asthmatic patients? Source: Annual Congress 2007 - New drugs for asthma Year: 2007 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011